ENTRY       D08083                      Drug
NAME        Vedolizumab (USAN);
            Vedolizumab (genetical recombination) (JAN);
            Entyvio (TN)
PRODUCT     VEDOLIZUMAB (Takeda Pharmaceuticals America)
FORMULA     C6428H10072N1732O2042S42
EXACT_MASS  145544.5805
MOL_WEIGHT  145633.8605
REMARK      Therapeutic category: 2399
            ATC code: L04AA33
            Product: D08083<JP/US>
EFFICACY    Anti-inflammatory, Integrin receptor antagonist, Anti-alpha4/beta7 integrin antibody
  DISEASE   Ulcerative colitis [DS:H01466]
            Crohn's disease [DS:H00286]
  TYPE      Monoclonal antibody
COMMENT     Treatment of ulcerative colitis and Crohn's disease
TARGET      ITGA4/ITGB7 [HSA:3676 3695] [KO:K06483 K06590]
  PATHWAY   hsa04512(3676+3695)  ECM-receptor interaction
            hsa04514(3676+3695)  Cell adhesion molecules
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA33 Vedolizumab
                  D08083  Vedolizumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Selective Adhesion-Molecule Inhibitor
                Vedolizumab
                 D08083  Vedolizumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              23  Digestive organ agents
               239  Miscellaneous
                2399  Others
                 D08083  Vedolizumab (USAN); Vedolizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: other families
               Integrins
                ITGA4/ITGB7
                 D08083  Vedolizumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08083
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08083
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D08083
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08083
DBLINKS     CAS: 943609-66-3
            PubChem: 96024773
///
